Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen, Tetragenetics in Antibody Research Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Amgen, Tetragenetics in Antibody Research Pact

Will use Tetragenetics technology platform for antibody production

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tetragenetics Inc. has entered into a technology access and exclusive research license agreement with Amgen for an undisclosed surface antigen. Tetragenetics’ technology enables high-density heterologous expression of recombinant human membrane proteins on the cell surface of Tetrahymena thermophila. Immunogen preparations of the drug targets can be made in several formats and are designed to enhance antibody production against the extracellular portions of the target.
 
Dr. Ted Clark, founder and chief scientific officer of Tetragenetics, said, “Tetragenetics has created a unique capability for making antigens which enable the discovery and production of novel antibodies that target validated but previously difficult to produce membrane protein drug targets. Our agreement with Amgen marks the second major partnership for Tetragenetics and the first for this specific family of targets.”
 
Financial terms of the agreement were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics